During the Corona pandemic, experts from Helmholtz Munich helped to bring the situation under control as quickly as possible. Now they are preparing for the possibility of another pandemic: with new high-tech equipment and closely interlinked…
Daniel Krappmann about his new Research Unit "Signaling and Translation" at Helmholtz Munich
Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
Amyotrophic Lateral Sclerosis (ALS) is a non-curable degenerative disease of the motor nervous system. The cause of the disease is largely unknown: In addition to genetic factors, viruses are also suspected to be involved in the development of the…
Hepatitis B virus (HBV) infections remain a major global health problem – according to the World Health Organization (WHO) there are around 300 million HBV carriers worldwide. Current treatments rarely succeed in curing the infection. At present,…
The Review Board for Medicine of the Deutsche Forschungsgemeinschaft (DFG) has appointed Helmholtz Munich scientist Dr. Marcus Conrad as a new member of the DFG’s Hinterzarten Circle on Cancer Research. Marcus Conrad succeeds Prof. Greten from…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: